Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments

• Tipo: Artigo em Revista Científica Internacional
• Data: 2023

Autores

Martins, RS (Autor) Outra; Jesus, TT (Autor) Outra; Cardoso, L (Autor) Outra; Soares, P (Autor) FMUP; Vinagre, J (Autor) Outra

Revista

A Revista está pendente de validação pelos Serviços Administrativos.

Título: JOURNAL OF PERSONALIZED MEDICINE

Vol. 13

Página Final: 1132

ISSN: 2075-4426

Editora: MDPI

Indexação

ISI Web of Knowledge - 5 Citações

Scopus - 5 Citações

Outras Informações

ID Authenticus: P-00Y-V1B

DOI: 10.3390/jpm13071132

Abstract (EN): Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its low mutational burden, with point mutations in RET or RAS genes being the most common oncogenic events. MTC can be resistant to cytotoxic chemotherapy, and multitarget kinase inhibitors (MKIs) have been considered a treatment option. They act by inhibiting the activities of specific tyrosine kinase receptors involved in tumor growth and angiogenesis. Several tyrosine kinase inhibitors are approved in the treatment of advanced MTC, including vandetanib and cabozantinib. However, due to the significant number of adverse events, debatable efficiency and resistance, there is a need for novel RET-specific TKIs. Newer RET-specific TKIs are expected to overcome previous limitations and improve patient outcomes. Herein, we aim to review MTC signaling pathways, the most recent options for treatment and the applications for personalized medicine.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 23